ALLO - Allogene Therapeutics, Inc.
28.19 +0.74 (2.68%)
After hours: 4:11PM EST
| Previous close | 28.86 |
| Open | 28.65 |
| Bid | 27.43 x 800 |
| Ask | 27.44 x 1200 |
| Day's range | 27.37 - 29.40 |
| 52-week range | 23.37 - 33.96 |
| Volume | 628,336 |
| Avg. volume | 378,561 |
| Market cap | 3.346B |
| Beta (3Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings date | 5 Nov 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.80 |
- GlobeNewswire
Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.
- GlobeNewswire
Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting AlloCAR T™ Pipeline at 61st American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic.
- GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2019 Financial Results
Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM)Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory.
- GlobeNewswire
Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic Therapies for Hematologic Cancer Indications
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic T cell therapies for the treatment of diseases of high unmet need, today announced an exclusive worldwide collaboration and license agreement to research and develop induced pluripotent stem cell (iPSC) AlloCAR™ therapy products for initial application in non-Hodgkin lymphoma, leukemia and multiple myeloma. Under the partnership, Allogene and Notch will create allogeneic cell therapy candidates from T cells or natural killer (NK) cells using Notch’s Engineered Thymic Niche (ETN) platform.
- GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2019 Financial Results on November 5, 2019
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.
- GlobeNewswire
Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T CellsResearch Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul.
- Simply Wall St.
When Will Allogene Therapeutics, Inc. (NASDAQ:ALLO) Come Back To Market?
Trailing twelve-month data shows us that Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) earnings loss has accumulated to...
- GlobeNewswire
Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan Stanley 17th Annual Global Healthcare Conference. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Motley FoolAllogene Therapeutics Inc (ALLO) Q2 2019 Earnings Call Transcript
ALLO earnings call for the period ending June 30, 2019.
- GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2019 Financial Results
ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Advances with Five Clinical Trial Sites OpenInvestigational New Drug (IND).
- GlobeNewswire
Allogene Therapeutics Appoints Rafael G. Amado, M.D. as Executive Vice President of Research and Development and Chief Medical Officer
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Rafael G. Amado, M.D., as Executive Vice President of Research and Development and Chief Medical Officer. In this new position, Dr. Amado will lead Allogene’s clinical and research functions with the goal of rapidly advancing our pipeline of allogeneic CAR T therapies for hematologic and solid tumors. Dr. Amado’s addition to the senior leadership team at Allogene reunites him with many former colleagues, including Arie Belldegrun, M.D. FACS, Executive Chairman and Co-Founder, who previously worked with Dr. Amado at UCLA and David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, who worked with him at UCLA and Amgen.
- GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., July 29, 2019 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage.
- GlobeNewswire
Allogene Therapeutics Announces FDA Clearance of the IND for ALLO-715, a BCMA Allogeneic CAR T (AlloCAR T™) Therapy
ALLO-715 Utilizes Gene-Editing of TRAC and CD52 Loci to Enable Allogeneic CAR T TherapyALLO-715 will be Evaluated in Combination with ALLO-647, Allogene’s Proprietary anti-CD52.
- GlobeNewswire
Allogene Therapeutics Announces June 2019 Investor Conference Schedule
SOUTH SAN FRANCISCO, Calif., May 29, 2019 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.
Motley FoolAllogene Therapeutics Inc (ALLO) Q1 2019 Earnings Call Transcript
ALLO earnings call for the period ending March 31, 2019.
- GlobeNewswire
Allogene Therapeutics Reports First Quarter 2019 Financial Results
Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)Investigational New Drug (IND) Application Submitted to the U.S. Food &.
- Motley Fool
2 Big Biotech Stock Upgrades: Can They Reach These Targets?
Investment-bank analysts think these drugmakers are worth a lot more than the stock market does at the moment.
- GlobeNewswire
Allogene Therapeutics Announces Expansion of Scientific Advisory Board
Newly Appointed Members Include Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. SOUTH SAN FRANCISCO, Calif., May 01, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. to its Scientific Advisory Board (SAB). The SAB comprises experts across oncology, immunology, cell therapy, drug discovery and development.
- GlobeNewswire
Allogene Therapeutics to Report First Quarter 2019 Financial Results on May 7, 2019
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2019 financial results on Tuesday, May 7, 2019, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 5:30 AM Pacific Time/8:30 AM Eastern Time. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
- GlobeNewswire
Allogene Therapeutics Announces Publication of Preclinical Study Results in Molecular Therapy Highlighting Potential for ALLO-715 (an Anti-BCMA AlloCAR T™ Therapy) in Multiple Myeloma
Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up ManufacturingALLO-715 Investigational New Drug Application and Phase 1.
- GlobeNewswire
Allogene Therapeutics Announces April 2019 Investor Conference Schedule
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Jefferies Immuno-Oncology Cell Therapy Summit in April 2019. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
- GlobeNewswire
Allogene Therapeutics Presents Preclinical Data Demonstrating the Potential of AlloCAR T™ Therapy in Renal Cell Carcinoma (RCC) at the 2019 AACR Annual Meeting
Anti-CD70 AlloCAR T™ Could Be Optimized to Eliminate Both CD70 Low and High Expressing Target Cells, and Manufactured in a Large-Scale ProcessCD70, Present on Both Hematologic.
- Simply Wall St.
All You Need To Know About Allogene Therapeutics, Inc.’s (NASDAQ:ALLO) Financial Health
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Allogene Therapeutics, Inc. (NASDAQ:ALLO) with a market-capitalization of US$3.2b, rarely draw their attention. However, generally ignored mid-capsRead More...
- GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for.
